192 related articles for article (PubMed ID: 20030419)
1. Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting.
Pariente A; Sanctussy DJ; Miremont-Salamé G; Moore N; Haramburu F; Fourrier-Réglat A;
CNS Drugs; 2010 Jan; 24(1):55-63. PubMed ID: 20030419
[TBL] [Abstract][Full Text] [Related]
2. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).
Tavassoli N; Sommet A; Lapeyre-Mestre M; Bagheri H; Montrastruc JL
Drug Saf; 2007; 30(11):1063-71. PubMed ID: 17973542
[TBL] [Abstract][Full Text] [Related]
3. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
[TBL] [Abstract][Full Text] [Related]
4. Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Ali TB; Schleret TR; Reilly BM; Chen WY; Abagyan R
PLoS One; 2015; 10(12):e0144337. PubMed ID: 26642212
[TBL] [Abstract][Full Text] [Related]
5. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
[TBL] [Abstract][Full Text] [Related]
7. Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings.
Rani FA; Byrne PJ; Murray ML; Carter P; Wong IC
Drug Saf; 2009; 32(4):325-33. PubMed ID: 19388723
[TBL] [Abstract][Full Text] [Related]
8. Drug-related nephrotoxic and ototoxic reactions : a link through a predictive mechanistic commonality.
Verdel BM; van Puijenbroek EP; Souverein PC; Leufkens HG; Egberts AC
Drug Saf; 2008; 31(10):877-84. PubMed ID: 18759511
[TBL] [Abstract][Full Text] [Related]
9. Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database.
Moulis G; Sommet A; Durrieu G; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
Br J Clin Pharmacol; 2012 Jul; 74(1):201-4. PubMed ID: 22257367
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
11. Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics.
Minjon L; van den Ban E; de Jong E; Souverein PC; Egberts TCG; Heerdink ER
J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):124-132. PubMed ID: 30676073
[TBL] [Abstract][Full Text] [Related]
12. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Nordberg A; Svensson AL
Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical adverse drug reactions: descriptive analysis of French reports.
Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H
Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024
[TBL] [Abstract][Full Text] [Related]
14. Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French PharmacoVigilance Database.
Montastruc F; Rouanet S; Gardette V; Rousseau V; Bagheri H; Montastruc JL
Eur J Clin Pharmacol; 2015 Jul; 71(7):891-5. PubMed ID: 25991052
[TBL] [Abstract][Full Text] [Related]
15. A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues.
Hasford J; Bruchmann F; Lutz M; Thürmann P; Schmiedl S
Eur J Clin Pharmacol; 2021 Nov; 77(11):1697-1704. PubMed ID: 34143228
[TBL] [Abstract][Full Text] [Related]
16. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
[TBL] [Abstract][Full Text] [Related]
17. Are non-serious adverse reactions to psychiatric drugs really non-serious?
Pozzi M; Bertella S; Cattaneo D; Molteni M; Perrone V; Carnovale C; Antoniazzi S; Clementi E; Radice S
J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):394-400. PubMed ID: 23952186
[TBL] [Abstract][Full Text] [Related]
18. The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.
Montastruc F; Sommet A; Bondon-Guitton E; Durrieu G; Bui E; Bagheri H; Lapeyre-Mestre M; Schmitt L; Montastruc JL
Eur J Clin Pharmacol; 2012 May; 68(5):767-75. PubMed ID: 22116460
[TBL] [Abstract][Full Text] [Related]
19. Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol).
Tavassoli N; Lapeyre-Mestre M; Sommet A; Montastruc JL;
Br J Clin Pharmacol; 2009 Sep; 68(3):422-6. PubMed ID: 19740400
[TBL] [Abstract][Full Text] [Related]
20. The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System.
Morris R; Umeukeje G; Bu K; Cheng F
J Alzheimers Dis; 2021; 83(3):1061-1071. PubMed ID: 34397417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
